{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 participant had DOR record","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"9.5"},{"comment":"Only 1 participant had DOR record","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"DOR is defined as the time from first documentation of CR or PR to date of first documentation of objective progression, or death due to any cause, or time of censoring, whichever occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.","id":"OG000","title":"PF-07209960 20 mg SC"},{"description":"Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.","id":"OG001","title":"PF-07209960 30 mg SC"}],"paramType":"MEDIAN","populationDescription":"The full analysis set included all enrolled participants.","reportingStatus":"POSTED","timeFrame":"Baseline through up to 2 years or until disease progression","title":"Duration of Response (DOR) Based on Investigator Assessment in Participants With Confirmed Response","type":"SECONDARY","unitOfMeasure":"Months"}